☰

Daniel P. Walker, Ph.D. - Publications

Affiliations: 
Indiana University, Bloomington, Bloomington, IN, United States 
Area:
total synthesis
Tree Info Similar researchers PubMed Report error

26 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Schnute ME, Benoit SE, Buchler IP, Caspers N, Grapperhaus ML, Han S, Hotchandani R, Huang N, Hughes RO, Juba BM, Kim KH, Liu E, McCarthy E, Messing D, Miyashiro JS, ... ... Walker DP, et al. Aminopyrazole Carboxamide Bruton's Tyrosine Kinase Inhibitors. Irreversible to Reversible Covalent Reactive Group Tuning. Acs Medicinal Chemistry Letters. 10: 80-85. PMID 30655951 DOI: 10.1021/Acsmedchemlett.8B00461  0.332
2019 Walker DP, Harris GD, Carroll JN, Boehm TL, McReynolds MD, Struble JR, van Herpt J, van Zwieten D, Koeller KJ, Bore M. A new process to prepare 3,6-dichloro-2-hydroxybenzoic acid, the penultimate intermediate in the synthesis of herbicide dicamba Tetrahedron Letters. 60: 1032-1036. DOI: 10.1016/J.Tetlet.2019.03.024  0.301
2017 Stepan AF, Claffey MM, Reese MR, Balan G, Barreiro G, Barricklow J, Bohanon MJ, Boscoe BP, Cappon GD, Chenard LK, Cianfrogna J, Chen L, Coffman KJ, Drozda SE, Dunetz JR, ... ... Walker DP, et al. Discovery and Characterization of (R)-6-Neopentyl-2-(pyridin-2-ylmethoxy)-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-one (PF-06462894), an Alkyne-Lacking Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator Profiled in both Rat and Non-human Primates. Journal of Medicinal Chemistry. PMID 28817277 DOI: 10.1021/Acs.Jmedchem.7B00604  0.325
2015 Blount KF, Megyola C, Plummer M, Osterman D, O'Connell T, Aristoff P, Quinn C, Chrusciel RA, Poel TJ, Schostarez HJ, Stewart CA, Walker DP, Wuts PG, Breaker RR. Novel Riboswitch-Binding Flavin Analog That Protects Mice against Clostridium difficile Infection without Inhibiting Cecal Flora. Antimicrobial Agents and Chemotherapy. 59: 5736-46. PMID 26169403 DOI: 10.1128/Aac.01282-15  0.314
2014 Zhang L, Balan G, Barreiro G, Boscoe BP, Chenard LK, Cianfrogna J, Claffey MM, Chen L, Coffman KJ, Drozda SE, Dunetz JR, Fonseca KR, Galatsis P, Grimwood S, Lazzaro JT, ... ... Walker DP, et al. Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator. Journal of Medicinal Chemistry. 57: 861-77. PMID 24392688 DOI: 10.1021/Jm401622K  0.351
2013 Daniels JS, Lai Y, South S, Chiang PC, Walker D, Feng B, Mireles R, Whiteley LO, McKenzie JW, Stevens J, Mourey R, Anderson D, Davis Ii JW. Inhibition of hepatobiliary transporters by a novel kinase inhibitor contributes to hepatotoxicity in beagle dogs. Drug Metabolism Letters. 7: 15-22. PMID 24138031 DOI: 10.2174/18723128112066660018  0.317
2013 Walker DP, Arhancet GB, Lu HF, Heasley SE, Metz S, Kablaoui NM, Franco FM, Hanau CE, Scholten JA, Springer JR, Fobian YM, Carter JS, Xing L, Yang S, Shaffer AF, et al. Synthesis and biological evaluation of substituted benzoxazoles as inhibitors of mPGES-1: use of a conformation-based hypothesis to facilitate compound design. Bioorganic & Medicinal Chemistry Letters. 23: 1120-6. PMID 23298810 DOI: 10.1016/J.Bmcl.2012.11.107  0.393
2013 Arhancet GB, Walker DP, Metz S, Fobian YM, Heasley SE, Carter JS, Springer JR, Jones DE, Hayes MJ, Shaffer AF, Jerome GM, Baratta MT, Zweifel B, Moore WM, Masferrer JL, et al. Discovery and SAR of PF-4693627, a potent, selective and orally bioavailable mPGES-1 inhibitor for the potential treatment of inflammation. Bioorganic & Medicinal Chemistry Letters. 23: 1114-9. PMID 23260349 DOI: 10.1016/J.Bmcl.2012.11.109  0.407
2013 Walker DP, Rogier DJ. Preparation of Novel Bridged Bicyclic Thiomorpholines as Potentially Useful Building Blocks in Medicinal Chemistry Synthesis. 45: 2966-2970. DOI: 10.1055/S-0033-1338528  0.35
2012 Bhattacharya SK, Aspnes GE, Bagley SW, Boehm M, Brosius AD, Buckbinder L, Chang JS, Dibrino J, Eng H, Frederick KS, Griffith DA, Griffor MC, Guimarães CR, Guzman-Perez A, Han S, ... ... Walker DP, et al. Identification of novel series of pyrazole and indole-urea based DFG-out PYK2 inhibitors. Bioorganic & Medicinal Chemistry Letters. 22: 7523-9. PMID 23153798 DOI: 10.1016/J.Bmcl.2012.10.039  0.343
2012 Walker DP, Eklov BM, Bedore MW. Practical synthesis of 3-oxa-6-azabicyclo[31.1]heptane hydrotosylate; A novel morpholine-based building block Synthesis (Germany). 44: 2859-2862. DOI: 10.1055/S-0032-1316748  0.353
2012 Walker DP, Bedore MW. Concise synthesis of N 3- and N 6-monoprotected 3,6-diazabicyclo[3.1.1]heptanes; Useful intermediates for the preparation of novel bridged bicyclic piperazines Tetrahedron Letters. 53: 6332-6334. DOI: 10.1016/J.Tetlet.2012.08.156  0.332
2011 Walker DP, Heasley SE, MacInnes A, Anjeh T, Lu HF, Fobian YM, Collins JT, Vazquez ML, Mao MK. A practical synthesis of [(1 S,3 S)-3-aminocyclohexyl]methanol and 2-[(1 S,3 S)-3-aminocyclohexyl]propan-2-ol, useful intermediates for the preparation of novel m PGES-1 inhibitors Synlett. 2959-2962. DOI: 10.1055/S-0031-1289884  0.313
2011 Wishka DG, Beagley P, Lyon J, Farley KA, Walker DP. A concise synthesis of 6-oxa-3-azabicyclo[31.1]heptane hydrotosylate Synthesis. 2619-2624. DOI: 10.1055/S-0030-1260116  0.352
2011 Wishka DG, Walker DP. Synthesis of (±)-6-oxa-3-azabicyclo[3.1.1]heptan-2-thione: A potential synthon for the preparation of novel heteroaryl-annulated bicyclic morpholines Tetrahedron Letters. 52: 4713-4715. DOI: 10.1016/J.Tetlet.2011.07.017  0.322
2010 Kalgutkar AS, Griffith DA, Ryder T, Sun H, Miao Z, Bauman JN, Didiuk MT, Frederick KS, Zhao SX, Prakash C, Soglia JR, Bagley SW, Bechle BM, Kelley RM, Dirico K, ... ... Walker DP, et al. Discovery tactics to mitigate toxicity risks due to reactive metabolite formation with 2-(2-hydroxyaryl)-5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3h)-one derivatives, potent calcium-sensing receptor antagonists and clinical candidate(s) for the treatment of osteoporosis. Chemical Research in Toxicology. 23: 1115-26. PMID 20507089 DOI: 10.1021/Tx100137N  0.352
2010 Walker DP, Strohbach JW, McGlynn MA, Lu HF. A practical and stereoselective synthesis of (+/-)-trans-4- benzyloctahydropyrrolo[3,4-b][1,4]oxazine Journal of Heterocyclic Chemistry. 47: 1095-1103. DOI: 10.1002/Jhet.476  0.349
2009 Didiuk MT, Griffith DA, Benbow JW, Liu KK, Walker DP, Bi FC, Morris J, Guzman-Perez A, Gao H, Bechle BM, Kelley RM, Yang X, Dirico K, Ahmed S, Hungerford W, et al. Short-acting 5-(trifluoromethyl)pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as orally-active calcium-sensing receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 19: 4555-9. PMID 19625189 DOI: 10.1016/J.Bmcl.2009.07.004  0.34
2009 Walker DP, Zawistoski MP, McGlynn MA, Li JC, Kung DW, Bonnette PC, Baumann A, Buckbinder L, Houser JA, Boer J, Mistry A, Han S, Xing L, Guzman-Perez A. Sulfoximine-substituted trifluoromethylpyrimidine analogs as inhibitors of proline-rich tyrosine kinase 2 (PYK2) show reduced hERG activity. Bioorganic & Medicinal Chemistry Letters. 19: 3253-8. PMID 19428251 DOI: 10.1016/J.Bmcl.2009.04.093  0.403
2009 Boyer D, Bauman JN, Walker DP, Kapinos B, Karki K, Kalgutkar AS. Utility of metaSite in improving metabolic stability of the neutral indomethacin amide derivative and selective cyclooxygenase-2 inhibitor 2-(1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)-A/-phenethyl-acetamide Drug Metabolism and Disposition. 37: 999-1008. PMID 19196840 DOI: 10.1124/Dmd.108.026112  0.355
2008 Walker DP, Bi FC, Kalgutkar AS, Bauman JN, Zhao SX, Soglia JR, Aspnes GE, Kung DW, Klug-McLeod J, Zawistoski MP, McGlynn MA, Oliver R, Dunn M, Li JC, Richter DT, et al. Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): structure-activity relationships and strategies for the elimination of reactive metabolite formation. Bioorganic & Medicinal Chemistry Letters. 18: 6071-7. PMID 18951788 DOI: 10.1016/J.Bmcl.2008.10.030  0.407
2008 Acker BA, Jacobsen EJ, Rogers BN, Wishka DG, Reitz SC, Piotrowski DW, Myers JK, Wolfe ML, Groppi VE, Thornburgh BA, Tinholt PM, Walters RR, Olson BA, Fitzgerald L, Staton BA, ... ... Walker DP, et al. Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor: in vitro and in vivo activity. Bioorganic & Medicinal Chemistry Letters. 18: 3611-5. PMID 18490160 DOI: 10.1016/J.Bmcl.2008.04.070  0.349
2008 Walker DP, Acker BA, Jon Jacobsen E, Wishka DG. Preparation of novel azabicyclic amines and α7 nicotinic acetylcholine receptor activity of derived aryl amides Journal of Heterocyclic Chemistry. 45: 247-257. DOI: 10.1002/Jhet.5570450131  0.313
2006 Walker DP, Wishka DG, Piotrowski DW, Jia S, Reitz SC, Yates KM, Myers JK, Vetman TN, Margolis BJ, Jacobsen EJ, Acker BA, Groppi VE, Wolfe ML, Thornburgh BA, Tinholt PM, et al. Design, synthesis, structure-activity relationship, and in vivo activity of azabicyclic aryl amides as alpha7 nicotinic acetylcholine receptor agonists. Bioorganic & Medicinal Chemistry. 14: 8219-48. PMID 17011782 DOI: 10.1016/J.Bmc.2006.09.019  0.375
2006 Wishka DG, Walker DP, Yates KM, Reitz SC, Jia S, Myers JK, Olson KL, Jacobsen EJ, Wolfe ML, Groppi VE, Hanchar AJ, Thornburgh BA, Cortes-Burgos LA, Wong EH, Staton BA, et al. Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship. Journal of Medicinal Chemistry. 49: 4425-36. PMID 16821801 DOI: 10.1021/Jm0602413  0.331
1999 Walker DP, Grieco PA. Total synthesis of 5(R)- and 5(S)-polyandrane [11] Journal of the American Chemical Society. 121: 9891-9892. DOI: 10.1021/Ja992791E  0.476
Show low-probability matches.